Hybrid Modalities

Integrating Chemistry, Bioscience, and Analytical Insight for the Next Generation of Hybrid Therapeutics

We enable our partners to bridge the gap between chemistry and biology.

From peptide–oligo conjugates and TAC hybrids to molecular glues and beyond, we deliver the scientific understanding, integration, and infrastructure needed to create advanced hybrid therapeutics, optimised for stability, potency and delivery.

Hybrid Modalities & Conjugates

Content Index

Overview
Integrated capabilities for hybrid modalities
Dedicated laboratories for hybrid modalities
Connected capabilities
Why choose us
In our own words
FAQs

Quick filter:

The next generation of therapeutics blurs the boundaries between traditional modalities. Therapeutic innovation is moving toward constructs that combine multiple modalities within a single molecule. These new constructs encompass a growing diversity of designs and molecular architectures, purpose-built to solve complex biological problems that single modalities cannot address.

While these hybrid constructs offer unprecedented therapeutic potential, they also introduce new layers of complexity. Their multifunctional nature and often high potency demand orthogonal synthesis routes, robust purification processes, and rigorous CMC control. Variability in sequence, conjugation or impurity profiles can have a pronounced impact on potency, stability and toxicity. Addressing these challenges requires deep cross-disciplinary expertise and seamless integration between chemistry, analytics, and bioscience.

We bring together the expertise and disciplines required to address this challenge. Our integrated teams spanning small molecules, peptides, oligonucleotides, and bioscience collaborate seamlessly to design, synthesise, and characterise hybrid constructs with precision and control. By combining deep scientific understanding with rigorous CMC oversight, we bridge discovery and development to accelerate IND readiness and de-risk candidate nomination for these innovative programs.

Integrated Capabilities for Hybrid Modalities

Design & Discovery
Synthesis & Process Development
Analytical Characterisation
Bioscience and Translation
Purification & Separation

Design & Discovery

Our hybrid discovery programmes begin with custom design, integrating small molecules, peptides, or oligonucleotides into a single, purposeful construct. We develop conjugation strategies that enhance stability, tolerability, and targeted delivery, supported by early analytical and bioscience input to guide structure or sequence optimisation and candidate selection.

Synthesis & Process Development

We employ tailored chemistries to build multifunctional conjugates that combine diverse molecular types, including peptides, oligonucleotides, and small molecules. Controlled linker design and precise functionalisation ensure optimal performance, while alternative synthetic routes are evaluated to identify scalable, high-yield processes suitable for development and manufacture.

Analytical Characterisation

Our analytical scientists provide comprehensive hybrid molecule characterisation using LC-MS, HRMS, and ion-pairing LC methods. Stability, degradation, and impurity profiling are performed across multiple chemistries, supported by ICH Q14/Q2(R2)-aligned validation.

Bioscience and Translation

A dedicated bioscience team assesses biological activity, uptake, and PK/PD to inform candidate selection. Through iterative Design–Make–Test cycles, we connect chemical design with functional data, delivering cell-based assays that assess target engagement, stability, and efficacy. Data-driven insight ensures every molecule is optimised for both performance and therapeutic potential.

Purification & Separation

Our integrated purification platforms combine preparative HPLC and SFC for the isolation and refinement of complex hybrid constructs. Impurity isolation, purification, and characterisation are performed from milligram to multi-gram scale, ensuring clean, consistent material ready for analytical and biological evaluation.

Dedicated Laboratories for Hybrid Modalities

Integrated Modality Suites

State-of-the-art dedicated laboratories for oligonucleotides, peptides and small molecule synthesis, co-located with biology capabilities for fast iteration and streamlined workflow integration

Purification & Analytical Platforms

Advanced HPLC, SFC, and HRMS systems for complex molecules. Scalable process development and deep characterisation supporting CMC development

Bioscience Laboratory

Mechanistic and functional translational platform to assess efficacy, delivery and mode of action of complex medicines bridging discovery and development

High Potency Suites

OEB-5 & OEB-4 SafeBridge®-audited labs and ICH-compliant analytical platforms

Digital & Predictive Tools

Bayesian optimisation and DoE-driven design for data-rich development

1 / 8

Explore Our Connected Capabilities

Hybrid modalities thrive on integration

Our hybrid therapeutics expertise is strengthened by the full breadth of our platform. Explore the connected capabilities that power hybrid development, from small molecules and oligonucleotides to bioscience, analytical science, and beyond.

Why Choose Us

Cross-Modality Expertise – Deep, integrated knowledge across chemistry, bioscience, and analytics to tackle complex hybrid therapeutics
Knowledge and Knowhow in Hybrid Therapeutics – Experience delivering conjugates, molecular glues, and multifunctional scaffolds
End-to-End Integration – Seamless workflow from design to purification and biological evaluation, ensuring quality and reproducibility
Data-Driven Collaboration – Co-located teams accelerating decisions through shared connectivity and communication
Trusted Experience – Partnered with 100+ biotech and pharma organisations worldwide

1 / 1

The success of hybrid modalities relies on collaboration - between scientists, between disciplines, and between partners. By bridging chemistry and biology within one connected team, we empower innovators to advance their molecules with confidence and speed.

Loic Roux

Technical Director, New Modalities - Drug Discovery

Frequently Asked Questions

What are hybrid modality development services?

Hybrid modality development services involve designing and optimising therapeutic constructs that combine multiple modalities — such as small molecules, peptides, and oligonucleotides — within a single drug entity. At CatSci, our teams integrate chemistry, bioscience, and analytical expertise to develop these complex therapeutics, ensuring stability, potency, and manufacturability from design to translation.

How does CatSci support conjugate and hybrid therapeutic development?

CatSci supports conjugate and hybrid therapeutic development through end-to-end integration of chemistry, biology, and analytics. We design custom conjugation strategies, optimise synthesis and purification processes, and provide analytical and bioscience insight to validate structure, function, and activity. Our hybrid modality development services accelerate discovery and de-risk CMC scale-up and regulatory readiness.

What makes CatSci’s approach to hybrid modalities unique?

CatSci’s hybrid modality approach unites chemistry and biology under one collaborative framework. With dedicated laboratories for oligonucleotides, peptides, and small molecules, we enable fast iteration, cross-functional data sharing, and seamless workflow integration. Our focus on translational science, CMC compliance, and sustainability makes CatSci a trusted partner for next-generation therapeutic innovation.